Welcome to our dedicated page for LMDX news (Ticker: LMDX), a resource for investors and traders seeking the latest updates and insights on LMDX stock.
LumiraDx Limited (Nasdaq: LMDX) delivers cutting-edge point-of-care diagnostic solutions through its portable testing platform. This page provides investors and healthcare professionals with essential updates on regulatory milestones, financial developments, and strategic partnerships shaping the company's trajectory in global diagnostics.
Key resources include press releases about FDA submissions, distribution agreements with European partners, and progress updates on Roche's acquisition of LumiraDx's platform business. Discover official announcements regarding new assay validations, financial results, and operational expansions across key markets.
Regular updates cover product innovations like the SARS-CoV-2 Ag Ultra test, partnership developments with healthcare distributors, and financial performance metrics. All content is verified through primary sources to ensure accuracy for investment research and industry analysis.
Bookmark this page for streamlined access to LumiraDx's latest corporate communications. Check back frequently to stay informed about developments impacting diagnostic accessibility and the company's position in rapid testing markets.
LumiraDx Limited (Nasdaq: LMDX) has announced a private subscription agreement to sell $56.5 million of 6.00% Convertible Senior Subordinated Notes due 2027. The offering, led by UBS O'Connor and supported by founder Ron Zwanziger, is expected to close on March 3, 2022. Following the offering, LumiraDx's projected cash balance would increase to $191.5 million. The notes will be convertible at an initial rate of 108.4346 common shares per $1,000 principal and will mature on March 1, 2027.
On January 14, 2022, LumiraDx (Nasdaq: LMDX) announced that its SARS-CoV-2 Antigen test effectively detects the Omicron variant of COVID-19, demonstrating comparable sensitivity to other variants. This follows previous tests confirming 100% agreement with RT-PCR methods up to Ct 33.0. The company asserts its testing capabilities ensure reliable detection of new variants, including Omicron, supported by FDA Emergency Use Authorization. LumiraDx's antigen test is positioned as a critical tool in managing the pandemic, validated by ongoing in-house studies and global collaborations.
LumiraDx (Nasdaq: LMDX) reported preliminary fourth-quarter 2021 revenues of $119 million, a rise from $101 million in Q4 2020. The full-year 2021 revenue is anticipated to reach $422 million, surpassing prior estimates of $367 million. The company attributes this growth to high demand for its COVID-19 testing solutions amid the Omicron variant surge. The anticipated sales include $77 million from its COVID-19 Antigen test and $24 million from Fast Lab Solutions, reflecting a 140% increase from Q3 2021.
LumiraDx (Nasdaq: LMDX) announced that its C-reactive protein (CRP) Test has received CE Marking, allowing it to be marketed in the European Union. This portable, fully automated test provides results within four minutes, facilitating the diagnosis of infections and inflammation. Particularly useful in assessing respiratory infections, the test can help reduce unnecessary antibiotic use, addressing antimicrobial resistance concerns. Shipments are set to begin shortly, following the company's recent CE marking for its SARS-CoV-2 & Flu A/B Antigen Test.
LumiraDx (Nasdaq: LMDX) has announced that its SARS-CoV-2 & Flu A/B Antigen Test has achieved CE Marking, allowing its launch in Europe amidst rising respiratory illness rates. This rapid test boasts a positive agreement of up to 95.5% for SARS-CoV-2 and significant performance for influenza detection. Shipments will begin shortly to aid in differentiating respiratory infections during the critical winter season. The company reassures that its tests remain effective against the Omicron variant. LumiraDx continues to expand its diagnostic capabilities across various diseases.
LumiraDx (NASDAQ: LMDX) has partnered with digital health non-profit Audere to launch a self-collected COVID-19 nasal specimen collection kit, authorized for use with the LumiraDx SARS-CoV-2 RNA STAR Complete assay. This collaboration aims to increase testing accessibility, allowing laboratories to integrate Audere's HealthPulse@home solution. The STAR Complete assay is currently authorized for emergency use by the FDA. This initiative aligns with LumiraDx's commitment to providing efficient and accessible testing solutions in various healthcare settings.
Audere has received Emergency Use Authorization (EUA) for HealthPulse@home from the FDA, enabling CLIA-certified laboratories to market their own self-collection COVID-19 specimen kits. This solution reduces costs and time for labs, facilitating quicker market access without individual FDA EUAs. HealthPulse@home allows for at-home or caregiver collection of nasal samples, enhancing testing options amidst ongoing COVID-19 challenges. Audere collaborates with partners like LumiraDx to further expand testing accessibility.
LumiraDx (Nasdaq: LMDX) announced a reissuance of the FDA Emergency Use Authorization (EUA) for its SARS-CoV-2 RNA STAR Complete testing solution. The updated EUA now allows for testing asymptomatic individuals, pooling samples from up to five people, and use with 384-well configuration on validated RT-PCR systems. The testing technology, which delivers results within 20 minutes, demonstrated 95.2% positive and 100% negative agreement in clinical studies. This expansion aims to enhance COVID-19 testing capacity and affordability in community programs.
LumiraDx (LMDX) announced its Q3 2021 financial results, reporting revenue of $109.1 million, significantly up from $13.9 million in Q3 2020. For the first nine months of 2021, revenue reached $303.2 million, compared to $26.9 million last year. The company expects full-year revenue to align with the consensus estimate of $367 million. Despite a gross margin of 36%, it faced challenges due to non-recurring production costs. Net income was reported at $84.8 million, equating to $0.46 per diluted share, influenced by accounting gains from a merger transaction.
LumiraDx (Nasdaq:LMDX) will announce its third quarter 2021 financial results on November 10, 2021. A conference call and webcast are scheduled for 8 AM ET to discuss the results and business highlights. The company specializes in next-generation point of care diagnostics, producing over 30 tests for various diseases. LumiraDx has a strong presence in community-based healthcare, deploying its solutions across multiple platforms. Investors can access a replay of the call on LumiraDx's investor website shortly after the event.
